Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

OncoZenge

5,36

 

SEK

Mindre end 1K følgere

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
+6,56%
+19,78%
-14,1%
+42,93%
+25,97%
+53,14%
+85,15%
-
-56,2%

OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Læs mere
Markedsværdi
62,78 mio. SEK
Aktieomsætning
-
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
21.8
2025

Delårsrapport Q2'25

20.11
2025

Delårsrapport Q3'25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse30.5.2025, 06.45

OncoZenge AB: OncoZenge Provides Update on Regulatory Status for Incoming Investment

OncoZenge
Pressemeddelelse15.5.2025, 09.35

Redeye: OncoZenge Q1 - Pieces falling into place

OncoZenge
Selskabsmeddelelse12.5.2025, 07.30

OncoZenge AB: OncoZenge: Investor Receives NDRC Approval

OncoZenge

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse25.4.2025, 06.30

OncoZenge AB: OncoZenge Provides Update on Regulatory Status for Incoming Investment

OncoZenge
Pressemeddelelse11.4.2025, 08.15

OncoZenge AB: OncoZenge enters licensing agreement with Avernus Pharma for BupiZenge™ in the GCC Region

OncoZenge
Selskabsmeddelelse11.4.2025, 07.45

OncoZenge AB: OncoZenge receives milestone payment from Molteni

OncoZenge
Pressemeddelelse4.4.2025, 08.00

OncoZenge AB: OncoZenge Strengthens Phase 3 Sponsor Team for Regulatory Affairs

OncoZenge
Pressemeddelelse2.4.2025, 14.40

OncoZenge AB: OncoZenge presents BupiZenge™ Phase 3 abstract at leading supportive cancer care conference in the US in June

OncoZenge
Selskabsmeddelelse28.3.2025, 07.00

OncoZenge AB enters exclusive agreement with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

OncoZenge
Pressemeddelelse4.3.2025, 15.00

OncoZenge AB receives positive assessment regarding the PCT-patent application for BupiZenge™

OncoZenge
Selskabsmeddelelse27.1.2025, 18.00

OncoZenge AB: OncoZenge enters into SEK 30.2 million investment agreement with new strategic investor Sichuan Yangtian Bio-Pharmaceutical, intended to be carried out through directed share issues

OncoZenge
Pressemeddelelse16.1.2025, 14.02

OncoZenge AB files PCT patent application for BupiZenge™

OncoZenge
Selskabsmeddelelse13.1.2025, 16.30

OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

OncoZenge
Pressemeddelelse26.11.2024, 10.30

Redeye: OncoZenge - Down, but not out

OncoZenge
Pressemeddelelse18.11.2024, 09.27

Redeye: OncoZenge Q3 2024 - Approaching lift-off

OncoZenge
Pressemeddelelse31.10.2024, 08.25

Redeye: Redeye Initiates Coverage of OncoZenge

OncoZenge
Selskabsmeddelelse18.10.2024, 08.00

OncoZenge AB intends to enter partnership with Pharmanovia for commercialization of BupiZenge™ in Europe, Middle East & North Africa

OncoZenge
Pressemeddelelse4.6.2024, 15.15

OncoZenge AB: OncoZenge participates in MASCC cancer care conference June 27-29

OncoZenge
Pressemeddelelse26.4.2024, 12.00

OncoZenge AB: OncoZenge Appoints Anna Asplind as Phase 3 Program Manager

OncoZenge
Pressemeddelelse25.4.2024, 12.40

OncoZenge AB: OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs

OncoZenge
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team